• 1
    Gubser C, Hue S, Kellam P, Smith GL. Poxvirus genomes: a phylogenetic analysis. J Gen Virol 2004; 85(Pt 1):10517.
  • 2
    Gordon SN, Cecchinato V, Andresen V et al. Smallpox vaccine safety is dependent on T cells and not B cells. J Infect Dis 2011; 203:104353.
  • 3
    Kammer AR, Ertl HC. Rabies vaccines: from the past to the 21st century. Hybrid Hybridomics 2002; 21:1237.
  • 4
    Johnson N, Cunningham AF, Fooks AR. The immune response to rabies virus infection and vaccination. Vaccine 2010; 28:3896901.
  • 5
    Thaiss CA, Kaufmann SH. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med 2010; 83:20915.
  • 6
    Ryan AA, Nambiar JK, Wozniak TM, Roediger B, Shklovskaya E, Britton WJ, Fazekas de St Groth B, Triccas JA. Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette–Guérin vaccine or Mycobacterium tuberculosis infection. J Immunol 2009; 182:71727.
  • 7
    Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698702.
  • 8
    Okiro EA, Bitira D, Mbabazi G, Mpimbaza A, Alegana VA, Talisuna AO, Snow RW. Increasing malaria hospital admissions in Uganda between 1999 and 2009. BMC Med 2011; 9:37.
  • 9
    Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 2001; 17:5937.
  • 10
    Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 2004; 363:1506.
  • 11
    Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266:16977.
  • 12
    Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011; 11:1029.
  • 13
    Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366:20128.
  • 14
    Lalvani A, Moris P, Voss G et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 1999; 180:165664.
  • 15
    Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines 2011; 10:58999.
  • 16
    Allsopp CE, Plebanski M, Gilbert S et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 1996; 26:19519.
  • 17
    Gilbert SC, Hill AV. Protein particle vaccines against malaria. Parasitol Today 1997; 13:3026.
  • 18
    Plebanski M, Gilbert SC, Schneider J et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998; 28:434555.
  • 19
    Schneider J, Gilbert SC, Hannan CM, Degano P, Prieur E, Sheu EG, Plebanski M, Hill AV. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999; 170:2938.
  • 20
    Moorthy VS, McConkey S, Roberts M et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003; 21:200411.
  • 21
    McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:72935.
  • 22
    Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74:593342.
  • 23
    Moorthy VS, Imoukhuede EB, Milligan P et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. Plos Med 2004; 1:e33.
  • 24
    Anderson RJ, Hannan CM, Gilbert SC et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol 2004; 172:3094100.
  • 25
    Webster DP, Dunachie S, Vuola JM et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005; 102:483641.
  • 26
    Bejon P, Peshu N, Gilbert SC et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006; 42:110210.
  • 27
    Bejon P, Mwacharo J, Kai OK et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 2006; 24:470915.
  • 28
    Bejon P, Mwacharo J, Kai O et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 2006; 1:e29.
  • 29
    Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, Hill AV. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002; 20:103945.
  • 30
    Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11:3517.
  • 31
    Kostense S, Koudstaal W, Sprangers M et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004; 18:12136.
  • 32
    Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003; 77:799803.
  • 33
    Radosevic K, Rodriguez A, Lemckert AA et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 2010; 17:168794.
  • 34
    Hill AV, Reyes-Sandoval A, O’Hara G et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6:7883.
  • 35
    Ersching J, Hernandez MI, Cezarotto FS et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 2010; 407:16.
  • 36
    Barouch DH, Kik SV, Weverling GJ et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011; 29:52039.
  • 37
    Dudareva M, Andrews L, Gilbert SC et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009; 27:35014.
  • 38
    Sheehy SH, Duncan CJA, Elias SC et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011; doi: 10.1038/mt.2011.176 [Epub ahead of print].
  • 39
    Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:188193.
  • 40
    Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010; 5:35761.
  • 41
    Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Eng J Med 2009; 361:220920.
  • 42
    Dorrell L, Yang H, Ondondo B et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 2006; 80:470516.
  • 43
    Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011; 10:65972.
  • 44
    Habersetzer F, Zarski J-P, Leroy V. A novel vectorized HCV therapeutic vaccine (TG4040): results of a phase I study in naive patients chronically infected by HCV. Denmark: 44th Annual Meeting of the European Association for the Study of the Liver, 2009.
  • 45
    Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103:1338.
  • 46
    Monto AS, Ansaldi F, Aspinall R et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009; 27:504353.
  • 47
    McMichael AJ, Gotch FM, Dongworth DW, Clark A, Potter CW. Declining T-cell immunity to influenza, 1977–82. Lancet 1983; 2:7624.
  • 48
    Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12:4854.
  • 49
    Berthoud TK, Hamill M, Lillie PJ et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011; 52:17.
  • 50
    Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:133945.
  • 51
    Hatherill M. Prospects for elimination of childhood tuberculosis: the role of new vaccines. Arch Dis Child 2011; 96:8516.
  • 52
    McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:12404.
  • 53
    Vordermeier HM, Villarreal-Ramos B, Cockle PJ et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009; 77:336473.
  • 54
    Sims RB. Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. J Cancer 2011; 2:3579.
  • 55
    Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH. Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines 2011; 10:899921.
  • 56
    Elkord E, Dangoor A, Drury NL et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother 2008; 31:8209.
  • 57
    Elkord E, Dangoor A, Burt DJ et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother 2009; 58:165767.
  • 58
    Tykodi SS, Thompson JA. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther 2008; 8:194753.
  • 59
    Webster RG, Robinson HL. DNA vaccines: a review of developments. BioDrugs 1997; 8:27392.
  • 60
    Baden LR, Blattner WA, Morgan C et al. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis 2011; 204:15419.
  • 61
    Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN. A new era in anticancer peptide vaccines. Cancer 2010; 116:207180.
  • 62
    Nardin E. The past decade in malaria synthetic peptide vaccine clinical trials. Hum Vaccin 2010; 6:2738.
  • 63
    Foged C, Hansen J, Agger EM. License to kill: formulation requirements for optimal priming of CD8+ CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci 2011; doi:10.1016/j.ejps.2011.08.016.
  • 64
    Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25:98104.
  • 65
    Alcock R, Cottingham MG, Rollier CS et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2010; 2:19ra2.
  • 66
    Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011; 23:37782.
  • 67
    Peruzzi D, Dharmapuri S, Cirillo A et al. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009; 27:1293300.
  • 68
    Goodman AL, Epp C, Moss D et al. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun 2010; 78:460112.
  • 69
    Letourneau S, Im EJ, Mashishi T et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007; 2:e984.
  • 70
    Liu J, Zhang S, Tan S, Zheng B, Gao GF. Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. Exp Biol Med (Maywood) 2011; 236:25367.
  • 71
    Berkley S, Bertram K, Delfraissy J-F et al . The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med 2010; 16:9819.
  • 72
    Makedonas G, Betts MR. Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev 2011; 239:10924.
  • 73
    Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity 2010; 33:51629.
  • 74
    Slota M, Lim JB, Dang Y, Disis ML. ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 2011; 10:299306.
  • 75
    McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008; 372:1894905.
  • 76
    Nitayaphan S, Pitisuttithum P, Karnasuta C et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004; 190:7026.
  • 77
    Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894903.